Search Results
60 results
Your search is now limited to «Clinical Trials» expert search.
ClinicalTrials.gov 01/14/2019 08:47
In Step 1, all participants will undergo study screening and enrollment.
More from ClinicalTrials.gov:
Benzinga 01/07/2019 07:00
About the Phase 2 Trial of Exebacase (CF-301): The study randomized one hundred and twenty-one (121) patients, 116 of which had confirmed Staph aureus bacteremia/endocarditis and received study drug and constituted the microbiological intent to treat (mITT ...
More from Benzinga:
GlobeNewswire 01/07/2019 07:00
Completing patient enrollment in both of our first Phase 2 studies marks an important milestone for our ongoing HBV clinical program and brings the potential of a cure closer to the millions of patients suffering from this chronic disease,” said Derek Small, President and Chief Executive ...
More from GlobeNewswire:
Business Wire 12/20/2018 11:45
In the Phase 1b part of the trial, 9 patients received escalating doses of TG4001 combined with a fixed dose of avelumab.
More from Business Wire:
WN.com 12/12/2018 07:45
CALGARY, Alberta and SAN DIEGO, Dec. 12, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), currently developing pelareorep, an intravenously delivered immuno-oncolytic virus, today announced that the first patient was treated in a phase 1 dose escalation study combining pelareorep and carfilzomib with Bristol-Myers Squibb's checkpoint inhibitor Opdivo® (nivolumab) to treat relapsed multiple myeloma patients.
More from WN.com:
Targeted Oncology 11/28/2018 10:57
A phase II trial is currently recruiting patients with Merkel cell carcinoma to participate in a single-arm study evaluating the safety and efficacy of INCMGA00012. 1 The open-label, multicenter study seeks to enroll 90 patients, including at least 52 patients who are treatment-naïve. In addition, only 40 patients who are chemotherapy-refractory will be allowed to participate.
Annals of Oncology 11/24/2018 19:00
Background: EBV associated malignancies exhibits high amplification of PD-L1 as distinguished from EBV non-associated malignancies (Kim et al. Gastroenterology 2015; Chen et al. Clinical Cancer Research 2013). The up-regulation of PD-L1 restricts antitumor effect of EBV-CTLs by immune tolerance and results in poor prognosis of patients. Our previous work has generated PD-1-disrupted CTLs by CRISPR-Cas9 system which could up-regulate IFN-γ production and enhance cytotoxicity in tumor cell lines and mouse model (Su et al. Oncoimmunology 2016).

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications